Prostate and pancreatic cancers are among the most common and difficult to treat cancers. Major dilemmas in the management of prostate cancer include the difficulty of discriminating between aggressive and indolent forms of the disease and the need for improved treatment of high-risk and castrate resistant metastatic disease. In the case of pancreatic cancer, the major problems are late diagnosis and high lethality. One major barrier to progress and an unmet need in both diseases is the relative absence of effective molecular imaging tracers/tools that can be used at the whole-body or intraoperative level, to guide patient management. Antibodies can provide highly specific probes for molecular targets, and can be engineered to optimize their utility as imaging agents for clinical use. During the previous project period, novel immunoPET imaging agents have been developed based on engineered antibody fragments directed towards Prostate Stem Cell Antigen (PSCA), a cell surface biomarker expressed by a majority of prostate and pancreatic cancers which is also a promising therapeutic target. Two fragment formats, cys-diabody and cys-minibody, which enable site-specific conjugation and labeling, have been produced with the goal of providing multifunctional fragments that can be radiolabeled with positron-emitting radionuclides 124I, 89Zr, or 18F, and/or conjugation with fluorescent labels for optical imaging. In the proposed work, fluorescently labeled PSCA cys-diabodies and cys-minibodies will be developed as intraoperative molecular imaging probes and their utility assessed in preclinical models. Dually labeled probes (PET/optical) will also be produced such that the same probe can be used for whole-body imaging followed by intraoperative visualization of local/regional spread. Finally, based on promising biodistribution and imaging studies of minibodies in patients, the therapeutic potential of radiolabeled anti-PSCA cys-minibodies will be explored, comparing non-residualizing (131I) and residualizing (177Lu) therapeutic radionuclides. Full biodistributions will be performed for dose estimations (mouse and human dosimetry), followed by radioimmunotherapy studies in preclinical models. Furthermore, the efficiacy of PSCA-targeted radioimmunotherapy in combination with androgen ablation or PARP inhibition will be evaluated. These fully humanized immunoPET probes can be readily translated to the clinic to address pressing questions in clinical management, including staging of newly diagnosed, recurrent and metastatic prostate and pancreatic cancers; improved selection and classification of patients for PSCA-targeted therapy; and monitoring disease response to therapy, and ultimately could serve as an efficacious delivery vehicle for tumor-targeted radiotherapy.

Public Health Relevance

Prostate and pancreatic cancers are among the most common and difficult to treat cancers, with major challenges in accurately diagnosing and staging disease, as well as monitoring response to therapy. One major barrier to progress is the absence of effective molecular imaging tracers/tools that can guide patient management. We are developing novel cancer-specific molecular imaging agents based on engineered antibodies that recognize PSCA, a cell surface biomarker expressed in pancreatic and prostate cancer, that can be used pre-operatively for staging, intraoperatively during surgery, and can ultimately be used to deliver targeted therapies directly to tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA174294-06
Application #
9765076
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Menkens, Anne E
Project Start
2013-04-01
Project End
2021-07-31
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
6
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Zettlitz, Kirstin A; Tsai, Wen-Ting K; Knowles, Scott M et al. (2018) Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody. J Nucl Med 59:1398-1405
Tsai, Wen-Ting K; Wu, Anna M (2018) Aligning physics and physiology: Engineering antibodies for radionuclide delivery. J Labelled Comp Radiopharm 61:693-714
Sonn, Geoffrey A; Behesnilian, Andrew S; Jiang, Ziyue Karen et al. (2016) Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time. Clin Cancer Res 22:1403-12
Freise, Amanda C; Wu, Anna M (2015) In vivo imaging with antibodies and engineered fragments. Mol Immunol 67:142-52
Knowles, Scott M; Tavaré, Richard; Zettlitz, Kirstin A et al. (2014) Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer. Clin Cancer Res 20:6367-78
Knowles, Scott M; Zettlitz, Kirstin A; Tavaré, Richard et al. (2014) Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody. J Nucl Med 55:452-9
Wu, Anna M (2014) Engineered antibodies for molecular imaging of cancer. Methods 65:139-47